TOP TEN perturbations for NM_000043 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000043
Selected probe(set): 204780_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000043 (204780_s_at) across 5392 perturbations tested by GENEVESTIGATOR:

doxorubicin study 3 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):5.575144
Number of Samples:2 / 2
Experimental doxorubicin study 3
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code:
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

ARC study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):4.797161
Number of Samples:2 / 2
Experimental ARC study 1
MCF7 cells treated with 2uM ARC (4-amino-6-hydrazino-7-beta-d-ribofuranosyl-7H-pyrrolo-(2, 3-d)-pyrimidine-5-carboxamide, NSC 188491) for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

immune cell study 10 (IgG memory B-cell) / immune cell study 10 (naive B-cell)

Relative Expression (log2-ratio):4.306736
Number of Samples:5 / 5
Experimental immune cell study 10 (IgG memory B-cell)
Class switched IgG memory B-cells (IgG+CD27+) isolated from peripheral blood of healthy adult donors (between 25 and 60 years of age). Mononuclear cells were isolated by Ficoll?Paque density centrifugation and CD19+ B-cells were enriched by magnetic cell separation using the MACS system or by negative selection using the EasySep Human B-Cell Enrichment Kit. B-cell suspensions were stained with anti-CD27 APC, anti-IgD PE?Cy7, anti-IgM FITC, and anti-IgG PE or anti-CD21 PE antibodies and sorted with a FACSDiva cell sorter as class switched IgG memory B-cells.
Control immune cell study 10 (naive B-cell)
Naive B-cells (IgM+IgD+CD27-) isolated from peripheral blood of healthy adult donors (between 25 and 60 years of age). Mononuclear cells were isolated by Ficoll?Paque density centrifugation and CD19+ B-cells were enriched by magnetic cell separation using the MACS system or by negative selection using the EasySep Human B-Cell Enrichment Kit. B-cell suspensions were stained with anti-CD27 APC, anti-IgD PE?Cy7, anti-IgM FITC, and anti-IgG PE or anti-CD21 PE antibodies and sorted with a FACSDiva cell sorter as naive B cells.

nutlin-3 (10uM); flagellin (500 ng/ml) study 1 (control vector) / flagellin study 4 (control vector; 500 ng/ml)

Relative Expression (log2-ratio):4.0087576
Number of Samples:6 / 2
Experimental nutlin-3 (10uM); flagellin (500 ng/ml) study 1 (control vector)
Human breast adenocarcinoma cells MCF-7 expressing wild type p53, stably transfected with control empty vector pSUPER, treated with nutlin-3 (10 uM) for 45 hours followed by an additional 3 hours treatment of nutlin-3 (10uM) and flagellin (500 ng/ml). Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS and 50 U/ml of penicillin, 50 ug/ml of streptomycin. ATC code:---
Control flagellin study 4 (control vector; 500 ng/ml)
Human breast adenocarcinoma cells MCF-7 expressing wild type p53, stably transfected with control empty vector pSUPER, treated with DMSO 0.1% for 45 hours followed by an additional 3 hours with flagellin (500 ng/ml). Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS and 50 U/ml of penicillin, 50 ug/ml of streptomycin.

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-3.9151363
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs? samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

CBFA2T3 depletion; IKKb(EE) overexpression study 1 / control transfected Reh cell sample

Relative Expression (log2-ratio):3.8979855
Number of Samples:2 / 2
Experimental CBFA2T3 depletion; IKKb(EE) overexpression study 1
Non-Hodgkin?s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing CBFA2T3-silencing shRNA and pRK5 vector overexpressing constitutively active form of I?B kinase ? (IKKb(EE)) along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.
Control control transfected Reh cell sample
Non-Hodgkin?s lymphoma cell line Reh was transiently transfected with pMSCVpuroH1 vector expressing scramled shRNA and empty pRK5 vector along with GFP-expressing vector pEGFP-N3. After 72 hours, GFP-positive cells were FACS-sorted and analyzed.

retina pigment epithelium study 2 (fetal) / retina pigment epithelium study 1 (fetal)

Relative Expression (log2-ratio):3.8650703
Number of Samples:12 / 6
Experimental retina pigment epithelium study 2 (fetal)
Human cultured fetal retina pigment epithelium samples obtained at gestation age between week 16-18.
Control retina pigment epithelium study 1 (fetal)
Human native fetal retina pigment epithelium samples obtained at gestation age between week 16-18.

pancreatic islet study 3 (re-differentiated; Whittier) / normal pancreatic islet sample

Relative Expression (log2-ratio):3.7305794
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; Whittier)
Human pancreatic islets were from 2 male donors (46 and 54 years old, body mass index 21kg/m2 and 31.6kg/m2). Islets cells were expanded for 4 weeks and re-differentiated for 1 week according to Whittier protocol. Re-differentiation phase: After four passages (1 month expansion), cells were dispersed with Versene and cultured in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml). After 1 week of culture on HTB-9-coated plates, cells were harvested and forced to reaggregate overnight.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

pancreatic islet study 3 (re-differentiated; NIH) / normal pancreatic islet sample

Relative Expression (log2-ratio):3.655302
Number of Samples:4 / 7
Experimental pancreatic islet study 3 (re-differentiated; NIH)
Pancreatic islet cells were expanded for 10 weeks and re-differentiated for 1 week according to National Institutes of Health (NIH) protocol. Re-differentiation phase: Expanded cells were cultured for 1 week in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml).
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-3.6189022
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.